Antioxidant treatment with quercetin ameliorates erectile dysfunction in streptozotocin-induced diabetic rats

Journal of Bioscience and Bioengineering

Volumn 112, Issue 3, 2011, Pages 215-218

  Zhang, Wei ^a   Wang, Yong ^a   Yang, Zengyue ^a   Qiu, Jianxin ^a   Ma, Jianjun ^a   Zhao, Zhiguang ^a   Bao, Tingyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Diabetes; Endothelial nitrogen monoxidum synthase; Erectile dysfunction; Oxidative stress; Quercetin

Indexed keywords

AFTER-TREATMENT; ANTIOXIDANT TREATMENT; CONTROL GROUPS; CORPUS CAVERNOSUM; DIABETIC RATS; ELECTROSTIMULATION; ELEVATED LEVEL; ENDOTHELIAL NITROGEN MONOXIDUM SYNTHASE; ERECTILE DYSFUNCTION; IN-CONTROL; INTRACAVERNOUS PRESSURE; INTRAVENOUS INJECTIONS; PATHOPHYSIOLOGICAL; QUERCETIN; SPRAGUE-DAWLEY RATS; STREPTOZOTOCIN; SUPEROXIDE DISMUTASE ACTIVITIES; SYNTHASES; WESTERN BLOT METHOD;

FATTY ACIDS; GLUCOSE; NITROGEN OXIDES; OXIDATIVE STRESS; OXYGEN; RATS; TISSUE;

PHENOLS;

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; NITRATE; NITRITE; QUERCETIN; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CAVERNOUS NERVE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; ELECTROSTIMULATION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; INTRACAVERNOUS PRESSURE; MALE; NERVE STIMULATION; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NERVE; PRESSURE; PRESSURE MEASUREMENT; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ERECTILE DYSFUNCTION; HUMANS; MALE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; PENIS; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

RATTUS;

EID: 80052266433     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2011.05.013     Document Type: Article

References (30)

1. McVary K.T. Clinical practice. Erectile dysfunction. N. Engl. J. Med. 2007, 357:2472-2481.
2. Teles A.G., Carreira M., Alarcão V., Sociol D., Aragüés J.M., Lopes L., Mascarenhas M., Costa J.G. Prevalence, severity, and risk factors for erectile dysfunction in a representative sample of 3,548 Portuguese men aged 40 to 69years attending primary healthcare centers: results of the Portuguese erectile dysfunction study. J. Sex. Med. 2008, 5:1317-1324.
3. Yang G., Pan C., Lu J. Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. Int. J. Impot. Res. 2010, 22:310-317.
4. Goldstein I., Young J.M., Fischer J., Bangerter K., Segerson T., Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diab. Care 2003, 26:777-783. Vardenafil Diabetes Study Group.
5. Sáenz de Tejada I., Anglin G., Knight J.R., Emmick J.T. Effects of tadalafil on erectile dysfunction in men with diabetes. Diab. Care 2002, 25:2159-2164.
6. Agarwal A., Nandipati K.C., Sharma R.K., Zippe C.D., Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J. Androl. 2006, 27:335-347.
7. Shukla N., Rossoni G., Hotston M., Sparatore A., Del Soldato P., Tazzari V., Persad R., Angelini G.D., Jeremy J.Y. Effect of hydrogen sulphide-donating sildenafil (ACS6) on erectile function and oxidative stress in rabbit isolated corpus cavernosum and in hypertensive rats. BJU Int. 2009, 103:1522-1529.
8. Valente E.G., Vernet D., Ferrini M.G., Qian A., Rajfer J., Gonzalez-Cadavid N.F. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229-244.
9. Bischoff S.C. Quercetin: potentials in the prevention and therapy of disease. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11:733-740.
10. Sanders R.A., Rauscher F.M., Watkins J.B. Effects of quercetin on antioxidant defense in streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol. 2001, 15:143-149.
11. Bhutada P., Mundhada Y., Bansod K., Bhutada C., Tawari S., Dixit P., Mundhada D. Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats. Neurobiol. Learn. Mem. 2010, 94:293-302.
12. Yao L.H., Jiang Y.M., Shi J., Tomás-Barberán F.A., Datta N., Singanusong R., Chen S.S. Flavonoids in food and their health benefits. Plant Foods Hum. Nutr. 2004, 59:113-122.
13. Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur. J. Pharmacol. 2008, 585:325-337.
14. Anjaneyulu M., Chopra K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin. Exp. Pharmacol. Physiol. 2004, 31:244-248.
15. Coskun O., Kanter M., Korkmaz A., Oter S. Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and beta-cell damage in rat pancreas. Pharmacol. Res. 2005, 51:117-123.
16. Dias A.S., Porawski M., Alonso M., Marroni N., Collado P.S., González-Gallego J. Quercetin decreases oxidative stress, NF-kappaB activation, and iNOS overexpression in liver of streptozotocin-induced diabetic rats. J. Nutr. 2005, 135:2299-2304.
17. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal. Biochem. 1984, 142:290-296.
18. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med. 1976, 15:212-216.
19. Gratzke C., Angulo J., Chitaley K., Dai Y.T., Kim N.N., Paick J.S., Simonsen U., Uckert S., Wespes E., Andersson K.E., Lue T.F., Stief C.G. Anatomy, physiology, and pathophysiology of erectile dysfunction. J. Sex. Med. 2010, 7:445-475.
20. Tamler R., Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. Postgrad. Med. J. 2010, 122:165-175.
21. Hnatyszyn O., Moscatelli V., Rondina R., Costa M., Arranz C., Balaszczuk A., Coussio J., Ferraro G. Flavonoids from Achyrocline satureioides with relaxant effects on the smooth muscle of Guinea pig corpus cavernosum. Phytomedicine 2004, 11:366-369.
22. Lines T.C., Ono M. FRS 1000, an extract of red onion peel, strongly inhibits phosphodiesterase 5A (PDE 5A). Phytomedicine 2006, 13:236-239.
23. Kawakami T., Urakami S., Hirata H., Tanaka Y., Nakajima K., Enokida H., Shiina H., Ogishima T., Tokizane T., Kawamoto K., other 3 authors Superoxide dismutase analog (tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence. Int. J. Impot. Res. 2009, 21:348-355.
24. Musicki B., Burnett A.L. Endothelial dysfunction in diabetic erectile dysfunction. Int. J. Impot. Res. 2007, 19:129-138.
25. Bivalacqua T.J., Usta M.F., Kendirci M., Pradhan L., Alvarez X., Champion H.C., Kadowitz P.J., Hellstrom W.J. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J. Sex. Med. 2005, 2:187-198.
26. Ushiyama M., Kuramochi T., Yagi S., Katayama S. Antioxidant treatment with alpha-tocopherol improves erectile function in hypertensive rats. Hypertens. Res. 2008, 31:1007-1013.
27. Strong T.D., Gebska M.A., Burnett A.L., Champion H.C., Bivalacqua T.J. Endothelium-specific gene and stem cell-based therapy for erectile dysfunction. Asian J. Androl. 2008, 10:14-22.
28. Bivalacqua T.J., Usta M.F., Champion H.C., Adams D., Namara D.B., Abdel-Mageed A.B., Kadowitz P.J., Hellstrom W.J. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J. Urol. 2003, 169:1911-1917.
29. Wan L.L., Xia J., Ye D., Liu J., Chen J., Wang G. Effects of quercetin on gene and protein expression of NOX and NOS after myocardial ischemia and reperfusion in rabbit. Cardiovasc. Ther. 2009, 27:28-33.
30. Khoo N.K., White C.R., Pozzo-Miller L., Zhou F., Constance C., Inoue T., Patel R.P., Parks D.A. Dietary flavonoid quercetin stimulates vasorelaxation in aortic vessels. Free Radic. Biol. Med. 2010, 49:339-347.